Product
RCT1100
1 clinical trial
1 indication
Indication
Primary Ciliary DyskinesiaClinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study, in Healthy Adult Participants and Open-Label Single Ascending Dose Study in Adults With Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Evaluate the Safety and Tolerability of RCT1100Status: Recruiting, Estimated PCD: 2024-09-21